Form 8-K

8-K — KORU Medical Systems, Inc.

Accession: 0001161697-26-000188

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0000704440

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — form_8-k.htm (Primary)

EX-99 — PRESS RELEASE, DATED AUGUST 5, 2026 (ex_99-1.htm)

GRAPHIC (koru_logo.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K CURRENT REPORT FOR 08-05-2026

8-K (Primary)

Filename: form_8-k.htm · Sequence: 1

Form 8-K

false

0000704440

2026-08-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported) August 5, 2026

KORU Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-12305

13-3044880

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

100 Corporate Drive, Mahwah, NJ

07430

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area

code (845) 469-2042

______________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing

is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction

A.2. below):

[_] Written communications pursuant to

Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule

14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant

to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant

to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

common stock, $0.01 par value

KRMD

The Nasdaq Stock Market

Indicate by check mark whether the registrant is an

emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark

if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards

provided pursuant to Section 13(a) of the Exchange Act. [_]

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

(a) Public Announcement or Release.

On August 5, 2026, KORU Medical Systems, Inc. (the

“Company”) issued a press release announcing its financial results for

the second fiscal quarter ended June 30, 2026 and updating financial guidance for the fiscal year ended December 31, 2025. The

Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. A related conference call will be held

on August 5, 2026 at 4:30pm Eastern Time.

KORU Medical

is making reference to non-GAAP financial measures in both the press release and the conference call. Our management believes that investors’

understanding of KORU Medical’s performance is enhanced by disclosing the non-GAAP financial measures of “adjusted EBITDA”

and “adjusted diluted EPS” (each as defined below) as a reasonable basis for comparison of our ongoing results of operations.

KORU Medical strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety

and cautions investors that the non-GAAP measures used by KORU Medical may differ from similar measures used by other companies, even

when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read

together with, the most comparable GAAP financial measures. A reconciliation of GAAP to non-GAAP results is provided in the attached Exhibit

99.1 press release.

We define

adjusted EBITDA as earnings (net (loss)/income) before depreciation and amortization, interest (income), net, litigation expense and stock-based

compensation expense. We believe that adjusted EBITDA is used by investors and other users of our financial statements as a supplemental

financial measure that, when viewed with our GAAP results and the accompanying reconciliation, we believe provides additional information

that is useful to gain an understanding of the factors and trends affecting our business. We also believe the disclosure of adjusted EBITDA

helps investors meaningfully evaluate and compare our cash flow generating capacity from quarter to quarter and year to year. adjusted

EBITDA is used by management as a supplemental internal measure for planning and forecasting overall expectations and for evaluating actual

results against such expectations.

We present

adjusted diluted earnings per share (“adjusted diluted EPS”) after eliminating items that we believe are not part of our ordinary

operations and affect the comparability of the periods presented. Adjusted diluted EPS includes adjustments from reported diluted earnings

per share for depreciation and amortization, interest (income), net, litigation expense and stock-based compensation expense. We believe

adjustments for these items allow investors to better understand our underlying operating results and facilitate comparisons between the

periods shown. Management uses adjusted diluted EPS as a supplemental internal measure for planning and forecasting overall expectations

and for evaluating actual results against such expectations.

The information contained in this Item 2.02 of the

Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any

filing of the Company under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as

expressly set forth by specific reference in such filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated August 5, 2026

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange

Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KORU Medical Systems, Inc.

(Registrant)

Date: August 5, 2026

By:

/s/ Adam Kalbermatten

Adam Kalbermatten

Chief Executive Officer

- 3 -

EX-99 — PRESS RELEASE, DATED AUGUST 5, 2026

EX-99

Filename: ex_99-1.htm · Sequence: 2

EXHIBIT 99.1

KORU Medical Systems Announces Second Quarter 2026 Results and Updates

Full Year 2026 Guidance

MAHWAH, NJ – August 5, 2026 – KORU

Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company

focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion

solutions, today reported financial results for the second quarter ended June 30, 2026. The Company also updated guidance for the full

year 2026.

Second Quarter 2026 and Recent Highlights

●

Net revenues grew 18% over the prior year period to $12.0 million

●

Gross profit grew 20% over the prior year period to $7.8 million, with gross margin of 65.1%

●

Net income improved 222% over the prior year period to $0.25 million

●

Acquired a connected monitoring technology asset, representing strategic investment to potentially enhance and differentiate the KORU platform through valuable real-time data insights into patient usage

●

Strategically shifting U.S. oncology market entry to focus on alternative higher volume molecules and withdrawing 510(k) application for the FreedomEDGE® with Phesgo® in the U.S.

●

Entered into a multi-year supply agreement to support operational strategy, product assurance, and long-term gross margin expansion

●

Refining full year 2026 guidance to include: Revenue of $47.5 - $48.5 million, gross margin of 62% - 64%, positive adjusted EBITDA, and year end cash balance of greater than $7.5 million

“We delivered record revenue, improved gross

margins and generated positive net income for the quarter, all of which demonstrate our ability to drive durable and profitable growth

in the subcutaneous drug delivery market,” said Adam Kalbermatten, President and CEO of KORU Medical. “We also acquired a

technology asset, representing a strategic investment in connected monitoring potential to further enhance the patient experience and

differentiate KORU’s value proposition to our partners.”

“Looking ahead for the remainder of 2026, we

expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled

syringes. We remain confident in the size of our international opportunity and view capturing this business only as a matter of timing.

Additionally, we have withdrawn our Phesgo® 510(k) application and shifted our U.S. oncology strategy to focus on alternative molecules

with higher infusion volumes. Overall, we are pleased with our performance in the quarter and are focused on executing our growth strategy

with operational discipline to drive durable value creation.”

2026 Second Quarter Financial Results

Three Months Ended June 30,

Change from Prior Year

% of Net Revenues

2026

2025

2026

2025

Net Revenues

Domestic Core

7,979,558

7,097,285

882,273

12.4%

66.2%

69.6%

International Core

3,469,558

2,180,111

1,289,447

59.1%

28.8%

21.4%

Total Core

11,449,116

9,277,396

2,171,720

23.4%

95.0%

91.0%

Pharma Services and Clinical Trials

596,304

917,404

(321,100

)

(35.0%

)

5.0%

9.0%

Total

12,045,420

10,194,800

1,850,620

18.2%

100.0%

Total net revenues increased $1.9 million, or 18.2%,

to $12.0 million for the three months ended June 30, 2026, as compared to $10.2 million in the prior year period. Domestic core revenues

were $8.0 million, an increase of 12.4% over the prior year period, primarily due to higher pump and consumable volumes, driven by new

patient starts and market share gains within new and existing accounts, supported by a strong underlying SCIg market. International core

revenues were $3.5 million, an increase of 59.1% over the prior year period, due to higher pump and consumable volumes, driven by distributor

purchases supporting pre-filled syringe (PFS) conversions, and new patient starts in established EU markets. Pharma services and clinical

trials net revenues were $0.6 million, a decrease of 35% over the prior year period, primarily due to lower clinical trial product revenues

related to customer order timing.

Gross profit increased $1.4 million, or 21.2%, to

$7.8 million in the three months ended June 30, 2026, as compared to $6.5 million in the prior year period, primarily driven by volume

growth. Gross margin increased to 65.1% in the three months ended June 30, 2026, as compared to 63.5% in the prior year period. The increase

in gross margin was primarily driven by lower manufacturing costs, and higher average selling prices.

Total operating expenses increased $0.4 million, or

6.3%, to $7.2 million for the second quarter of 2026 primarily driven by an increase of $0.6 million in selling, general, and administrative

expenses, and a decrease of $0.1 million in research and development expenses. The increase in selling, general and administrative expenses

was primarily driven by increases in compensation and benefits from new hires, and legal fees, partially offset by lower stock compensation,

recruiting, and consulting expenses.

Net income increased $0.5 million to $0.3 million

or $0.01 per diluted share for the second quarter of 2026, compared to a net loss of ($0.2) million, or ($0.01) per diluted share, for

the prior year period. Adjusted EBITDA for the quarter was $0.9 million, or $0.02 per adjusted diluted share versus $0.3 million or $0.01

per adjusted diluted share in the prior year period. A reconciliation of adjusted EBITDA and adjusted diluted EPS to the most directly

comparable GAAP measures is provided at the end of this press release.

Cash and cash equivalents were $8.3 million as of

June 30, 2026, reflecting cash usage of $0.5 million in the second quarter of 2026.

Updated 2026 Guidance

●

Narrowing full year 2026 net revenues to be between $47.5 - $48.5 million, representing growth of 15% - 18%

●

Raising full year 2026 gross margin to be between 62 - 64%

●

Reiterating positive adjusted EBITDA for the full year

●

Updating year end cash balance to be greater than $7.5 million to account for the technology acquisition

Conference Call and Webcast Details

The Company will host a live conference call and webcast

to discuss these results and provide a corporate update on Wednesday August 5, 2026, at 4:30 PM ET.

To participate in the call, please dial (877) 407-0784

(domestic) or (201) 689-8560 (international). The live webcast will be available on the IR Calendar on the News/Events page of the Investors

section of KORU Medical’s website.

Non-GAAP Measures

This press release includes the non-GAAP financial

measures “adjusted diluted EPS” and “adjusted EBITDA” that are not in accordance with, nor an alternate to, generally

accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based

on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or

superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges

that have a material effect on KORU Medical’s reported results and, therefore, should not be relied upon as the sole financial measures

to evaluate the Company’s financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction

with GAAP financial results. Reconciliations of the Company’s non-GAAP measures are included at the end of this press release.

- 2 -

About KORU Medical Systems

KORU Medical Systems develops, manufactures, and commercializes

innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world.

The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60® and FreedomEDGE®

Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HigH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which

received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory

infusion center by a healthcare professional. Through its Pharma Service and Clinical Trials business, KORU Medical provides products

for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of

customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

Forward-looking Statements

This press release contains forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are

not historical fact are forward-looking statements, including, but not limited to, financial guidance and expected operating performance

for fiscal 2026. Forward-looking statements discuss the Company’s current expectations and projections relating to its financial

position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by

words such as “potential”, “guidance”, and “expect”. Actual results may differ materially from the

results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties

that could cause actual results to differ from the results predicted include, among others, ability to adapt new technology, uncertainties

associated with inflation, tariffs, war and other geopolitical conflicts, customer ordering patterns, availability and costs of raw materials

and labor and our ability to recover such costs, future operating results, growth of new patient starts and the Ig market, our compliance

with Food and Drug Administration and foreign authority regulations and the outcome of regulatory audits, introduction and adoption of

competitive products, acceptance of and demand for new and existing products, ability to penetrate new markets, success in enforcing and

obtaining patents, reimbursement related risks, government regulation of the home health care industry, success of our research and development

effort, expanding the market of the Freedom System, demand in the SCIg market, availability of sufficient capital if or when needed, dependence

on key personnel, the impact of recent accounting pronouncements, and those risks and uncertainties included under the captions “Risk

Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on

our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the

attachments is as of August 5, 2026. Undue reliance should not be placed on the forward-looking statements in this press release, which

are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Investor Contact:

Louisa Smith

investor@korumedical.com

- 3 -

KORU MEDICAL SYSTEMS, INC.

BALANCE SHEETS

June 30,

December 31,

2026

2025

(UNAUDITED)

ASSETS

CURRENT ASSETS

Cash and cash equivalents

8,287,704

8,872,212

Accounts receivable, net

5,027,723

5,972,252

Inventory, net

4,511,126

3,678,131

Other receivables

1,064,909

557,653

Prepaid expenses and other current assets

622,655

908,542

TOTAL CURRENT ASSETS

19,514,117

19,988,790

Property and equipment, net

3,929,718

4,471,386

Intangible assets, net of accumulated amortization of $562,655 and $527,949 as of June 30, 2026 and December 31, 2025, respectively

1,663,318

684,841

Operating lease right-of-use assets

2,755,890

2,956,192

Other assets

98,970

TOTAL ASSETS

27,962,013

28,200,179

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

Accounts payable

2,912,589

2,267,473

Accrued expenses

2,869,568

4,828,830

Other liabilities

11,068

27,722

Accrued payroll and related taxes

807,832

531,972

Financing lease liability

148,592

124,913

Operating lease liability

430,173

413,448

TOTAL CURRENT LIABILITIES

7,179,822

8,194,358

Financing lease liability, net of current portion

71,409

78,675

Operating lease liability, net of current portion

2,659,265

2,879,224

TOTAL LIABILITIES

9,910,496

11,152,257

STOCKHOLDERS’ EQUITY

Common stock, $0.01 par value, 75,000,000 shares authorized, 50,172,404 and 49,790,934 shares issued 46,148,690 and 46,370,432 shares outstanding as of June 30, 2026, and December 31, 2025, respectively

501,724

497,909

Additional paid-in capital

56,527,047

52,449,339

Treasury stock, 4,018,526 and 3,438,526 shares as of June 30, 2026 and December 31, 2025, respectively, at cost

(6,405,793

)

(3,882,494

)

Accumulated deficit

(32,571,461

)

(32,016,832

)

TOTAL STOCKHOLDERS’ EQUITY

18,051,517

17,047,922

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

27,962,013

28,200,179

- 4 -

KORU MEDICAL SYSTEMS, INC.

STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

NET REVENUES

12,045,420

10,194,800

23,810,044

19,829,875

Cost of goods sold

4,199,212

3,719,031

8,732,447

7,307,771

Gross Profit

7,846,208

6,475,769

15,077,597

12,522,104

OPERATING EXPENSES

Selling, general and administrative

5,939,986

5,384,148

12,522,165

11,343,522

Research and development

1,069,200

1,194,789

2,385,804

2,309,398

Depreciation and amortization

210,031

209,487

407,561

426,844

Total Operating Expenses

7,219,217

6,788,424

15,315,530

14,079,764

Net Operating Income /(Loss)

626,991

(312,655

)

(237,933

)

(1,557,660

)

Non-Operating Income/(Expense)

Gain/(Loss) on currency exchange

(22,343

)

44,193

(45,493

)

49,782

Loss on disposal of fixed assets, net

(406,269

)

—

(406,269

)

—

Interest income, net

59,870

78,951

140,866

152,130

TOTAL OTHER (EXPENSE)/INCOME

(368,742

)

123,144

(310,896

)

201,912

INCOME / (LOSS) BEFORE INCOME TAXES

258,249

(189,511

)

(548,829

)

(1,355,748

)

Income Tax Expense

(5,800

)

(17,356

)

(5,800

)

(17,356

)

NET INCOME/(LOSS)

252,449

(206,867

)

(554,629

)

(1,373,104

)

NET INCOME / (LOSS) PER SHARE

Basic

0.01

(0.00

)

(0.01

)

(0.03

)

Diluted

0.01

(0.00

)

(0.01

)

(0.03

)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic

46,083,893

46,193,709

46,223,623

46,088,353

Diluted

49,509,437

46,193,709

46,223,623

46,088,353

- 5 -

KORU MEDICAL SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

June 30,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES

Net Loss

(554,629

)

(1,373,104

)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense and warrant expense

1,139,284

1,113,334

Depreciation and amortization

407,561

426,844

Loss on disposal of fixed assets

406,269

—

Non-cash leasing charges

(2,931

)

—

Changes in operating assets and liabilities:

Decrease/(Increase) in accounts receivable

944,529

805,133

Decrease/(Increase) in other receivables

(507,257

)

47,979

Decrease/(Increase) in inventory

(832,996

)

(1,144,175

)

Decrease/(Increase) in prepaid expenses and other assets

285,887

317,897

Increase/(Decrease) in accounts payable

645,116

(555,430

)

Increase/(Decrease) in accrued payroll and related taxes

275,860

(122,459

)

Increase/(Decrease) in other liabilities

(16,654

)

74,833

Increase/(Decrease) in accrued expenses

(1,959,263

)

(288,659

)

NET CASH FLOWS FROM OPERATING ACTIVITIES

230,776

(697,807

)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchases of property and equipment

(154,070

)

(472,252

)

Purchases of intangible assets

(461,035

)

(3,400

)

Capitalized software development costs

(52,147

)

—

NET CASH FLOWS FROM INVESTING ACTIVITIES

(667,252

)

(475,652

)

CASH FLOWS FROM FINANCING ACTIVITIES

Payments on insurance finance indebtedness

—

(271,152

)

Payments for taxes related to net share settlement of equity awards

(81,059

)

(27,536

)

Payments on finance lease liability, net of asset

(66,973

)

(54,084

)

NET CASH FLOWS FROM FINANCING ACTIVITIES

(148,032

)

(352,772

)

NET DECREASE IN CASH AND CASH EQUIVALENTS

(584,508

)

(1,526,231

)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

8,872,212

9,580,947

CASH AND CASH EQUIVALENTS, END OF PERIOD

8,287,704

8,054,716

Supplemental Information

Cash paid during the years for:

Interest

4,732

7,563

Income Taxes

5,800

17,356

Non-cash Financing Activity

During the six months ended June 30, 2026, the Company acquired an intangible asset for

$961,035, of which $500,000 was settled through the issuance of 125,628 shares of

common stock

- 6 -

KORU MEDICAL SYSTEMS, INC.

SUPPLEMENTAL INFORMATION

(UNAUDITED)

Three Months Ended

Six Months Ended

Reconciliation of GAAP Net Income / (Loss) to

June 30,

Non-GAAP Adjusted EBITDA:

2026

2025

2026

2025

GAAP Net Income / (Loss)

252,449

(206,867

)

(554,628

)

(1,373,104

)

Depreciation and Amortization

210,031

209,487

407,562

426,844

Interest (Income), Net

(59,870

)

(78,951

)

(140,866

)

(152,130

)

Stock-based Compensation Expense

457,773

415,744

1,139,284

1,113,344

Adjusted EBITDA

860,383

339,414

851,351

14,953

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING

Basic

46,083,893

46,193,709

46,223,623

46,088,353

Diluted

49,509,437

46,193,709

46,223,623

46,088,353

Three Months Ended

Six Months Ended

Reconciliation of Reported Diluted EPS to

June 30,

Non-GAAP Adjusted Diluted EPS:

2026

2025

2026

2025

Reported Diluted Earnings Per Share

0.01

(0.00

)

(0.01

)

(0.03

)

Depreciation and Amortization

0.00

0.01

Interest (Income), Net

(0.00

)

(0.00

)

(0.00

)

(0.00

)

Stock-based Compensation Expense

0.01

0.02

Adjusted Diluted EPS

0.02

0.01

0.02

0.00

- 7 -

GRAPHIC

Filename: koru_logo.jpg · Sequence: 3

Binary file (12861 bytes)

Download koru_logo.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity File Number

0-12305

Entity Registrant Name

KORU Medical Systems, Inc.

Entity Central Index Key

0000704440

Entity Tax Identification Number

13-3044880

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100 Corporate Drive

Entity Address, City or Town

Mahwah

Entity Address, State or Province

Entity Address, Postal Zip Code

07430

City Area Code

845

Local Phone Number

469-2042

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

common stock, $0.01 par value

Trading Symbol

KRMD

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration